These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 30628926)
1. SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma. Laurent E; Begueret H; Bonhomme B; Veillon R; Thumerel M; Velasco V; Brouste V; Hoppe S; Fournier M; Grellety T; MacGrogan G Am J Surg Pathol; 2019 Mar; 43(3):293-302. PubMed ID: 30628926 [TBL] [Abstract][Full Text] [Related]
2. Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer. Jamidi SK; Hu J; Aphivatanasiri C; Tsang JY; Poon IK; Li JJ; Chan SK; Cheung SY; Tse GM Histopathology; 2020 Dec; 77(6):936-948. PubMed ID: 32304249 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer. Krings G; Nystrom M; Mehdi I; Vohra P; Chen YY Hum Pathol; 2014 Nov; 45(11):2225-32. PubMed ID: 25150746 [TBL] [Abstract][Full Text] [Related]
4. Clinicopathological, immunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in triple-negative breast carcinoma. Harbhajanka A; Chahar S; Miskimen K; Silverman P; Harris L; Williams N; Varadan V; Gilmore H Hum Pathol; 2018 Oct; 80():163-169. PubMed ID: 29894722 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical Profile of Triple-Negative Breast Cancers: SOX10 and AR Dual Negative Tumors Have Worse Outcomes. Rammal R; Goel K; Motanagh SA; Carter GJ; Clark BZ; Fine JL; Harinath L; Villatoro TM; Yu J; Bhargava R Mod Pathol; 2024 Jul; 37(7):100517. PubMed ID: 38763422 [TBL] [Abstract][Full Text] [Related]
6. A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer. Tozbikian GH; Zynger DL Hum Pathol; 2019 Mar; 85():221-227. PubMed ID: 30468800 [TBL] [Abstract][Full Text] [Related]
7. The Added Value of SOX10 Immunohistochemistry to Other Breast Markers in Identifying Cytokeratin 5-Positive Triple Negative Breast Cancers as of Mammary Origin. Sejben A; Vörös A; Golan A; Zombori T; Cserni G Pathobiology; 2021; 88(3):228-233. PubMed ID: 33567441 [TBL] [Abstract][Full Text] [Related]
8. Cytokeratin 7, GATA3, and SOX-10 is a Comprehensive Panel in Diagnosing Triple Negative Breast Cancer Brain Metastases. Statz E; Jorns JM Int J Surg Pathol; 2021 Aug; 29(5):470-474. PubMed ID: 33543662 [TBL] [Abstract][Full Text] [Related]
9. Expression patterns of GATA3 and the androgen receptor are strongly correlated in patients with triple-negative breast cancer. Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH Hum Pathol; 2016 Sep; 55():190-5. PubMed ID: 27184484 [TBL] [Abstract][Full Text] [Related]
10. The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors. Sangoi AR; Shrestha B; Yang G; Mego O; Beck AH Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):229-37. PubMed ID: 25906123 [TBL] [Abstract][Full Text] [Related]
11. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer. Ni YB; Tsang JYS; Shao MM; Chan SK; Cheung SY; Tong J; To KF; Tse GM Breast Cancer Res Treat; 2018 May; 169(1):25-32. PubMed ID: 29340880 [TBL] [Abstract][Full Text] [Related]
12. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors. Yang Y; Lu S; Zeng W; Xie S; Xiao S Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704 [TBL] [Abstract][Full Text] [Related]
13. Combined SOX10 GATA3 is most sensitive in detecting primary and metastatic breast cancers: a comparative study of breast markers in multiple tumors. Aphivatanasiri C; Li J; Chan R; Jamidi SK; Tsang JY; Poon IK; Shao Y; Tong J; To KF; Chan SK; Tam F; Cheung SY; Shea KH; Tse GM Breast Cancer Res Treat; 2020 Nov; 184(1):11-21. PubMed ID: 32737715 [TBL] [Abstract][Full Text] [Related]
14. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes. Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285 [TBL] [Abstract][Full Text] [Related]
15. Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma. Dang DN; Raj G; Sarode V; Molberg KH; Vadlamudi RK; Peng Y Hum Pathol; 2015 Dec; 46(12):1829-35. PubMed ID: 26428280 [TBL] [Abstract][Full Text] [Related]
16. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers. Yoon EC; Wilson P; Zuo T; Pinto M; Cole K; Harigopal M Hum Pathol; 2020 Aug; 102():13-22. PubMed ID: 32565323 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung. Hattori Y; Yoshida A; Yoshida M; Takahashi M; Tsuta K Pathol Int; 2015 Jun; 65(6):286-92. PubMed ID: 25727644 [TBL] [Abstract][Full Text] [Related]
18. Strong androgen receptor expression can aid in distinguishing GATA3+ metastases. Boto A; Harigopal M Hum Pathol; 2018 May; 75():63-70. PubMed ID: 29408697 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance of Sox10 expression in triple-negative breast carcinoma. Jin L; Qin C; Qi X; Hong T; Yang X; Zhu X Transl Cancer Res; 2020 Sep; 9(9):5603-5613. PubMed ID: 35117924 [TBL] [Abstract][Full Text] [Related]
20. [Diagnostic value of combined application of GATA3, SOX10 and p16 in triple negative breast carcinomas]. Zhang DM; Zhai CJ; Feng XD; Wang CZ; Qiu JF; Wei JG Zhonghua Yi Xue Za Zhi; 2022 Mar; 102(10):735-740. PubMed ID: 35280018 [No Abstract] [Full Text] [Related] [Next] [New Search]